Ignite Creation Date:
2024-05-05 @ 10:17 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01070862
Status:
COMPLETED
Last Update Posted:
2010-02-18
First Post:
2010-02-17
Brief Title:
Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as ConsolidationMaintenance Treatment in Young and Elderly Patients 3 Randomized Studies
Sponsor:
University Hospital Caen
Organization:
University Hospital Caen
Study Overview
Official Title:
Multiple Myeloma Treatment With Thalidomide Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant MY-TAG or With a Conventional Chemotherapy MY-DECT and as ConsolidationMaintenance at Plateau Phase MY-PLAT
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAG 2002
Brief Summary:
The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line treatment of multiple myeloma as induction treatment in young patients with Dexamethasone before autotransplant and in elderly patients in combination with conventional chemotherapy and as consolidationmaintenance therapy in young and elderly patients at plateau-phase
Detailed Description:
MY-TAG Thalidomide as induction treatment before high dose therapy in young patients MY-DECT Thalidomide as induction treatment with conventional chemotherapy in elderly patients MY-PLAT Thalidomide and Dexamethasone at plateau-phase after high dose therapy or conventional chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None